Xenon Pharmaceuticals Inc XENE

NAS: XENE | ISIN: CA98420N1050 16:49

39,51 USD (-0,73%)

(-0,73%) 16:49

Grafiek Xenon Pharmaceuticals Inc

Grafiek Xenon Pharmaceuticals Inc

1 dag1d -0,73%
1 week1w -2,40%
1 maand1m -1,25%
3 maanden3m -18,40%
6 maanden6m 35,82%
1 jaar1j -6,24%
5 jaar5j 325,30%

Xenon Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

12 maart 2021 · Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares · Persbericht

10 maart 2021 · Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering · Persbericht

9 maart 2021 · Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares · Persbericht

8 maart 2021 · Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD) · Persbericht

1 maart 2021 · Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update · Persbericht

23 februari 2021 · Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results · Persbericht

22 februari 2021 · Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021 · Persbericht

Profiel Xenon Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Simon Pimstone

Werknemers: 236

Aandelen Xenon Pharmaceuticals Inc

Beurswaarde: 3,00 miljard USD

Effecten: 75,47 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 0,64

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe